Compare CMCO & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMCO | VIR |
|---|---|---|
| Founded | 1875 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 609.1M | 1.5B |
| IPO Year | 2002 | 2019 |
| Metric | CMCO | VIR |
|---|---|---|
| Price | $14.46 | $9.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $21.00 | $19.63 |
| AVG Volume (30 Days) | 393.2K | ★ 4.3M |
| Earning Date | 05-08-2026 | 05-25-2026 |
| Dividend Yield | ★ 1.84% | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $936,240,000.00 | $68,556,000.00 |
| Revenue This Year | $19.73 | N/A |
| Revenue Next Year | $82.91 | $925.73 |
| P/E Ratio | $48.70 | ★ N/A |
| Revenue Growth | ★ 3.27 | N/A |
| 52 Week Low | $11.78 | $4.16 |
| 52 Week High | $24.40 | $10.91 |
| Indicator | CMCO | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 19.96 | 57.65 |
| Support Level | $13.92 | $4.64 |
| Resistance Level | $16.02 | $10.91 |
| Average True Range (ATR) | 0.93 | 0.61 |
| MACD | -0.41 | -0.05 |
| Stochastic Oscillator | 2.74 | 49.69 |
Columbus McKinnon Corp is a designer, manufacturer, and marketer of intelligent motion solutions, including motion control products, technologies, automated systems, and services that efficiently and ergonomically move, lift, position, and secure materials. Its key products include hoists, crane components, precision conveyors, actuators, rigging tools, light rail workstations, and digital power and motion control systems. The company's targeted market verticals include general industries, process industries, industrial automation, and e-commerce/supply chain/warehousing among others. Geographically, the company generates a majority of its revenue from the United States and the rest from Germany, Canada, Asia Pacific, Latin America, Europe, the Middle East, and Africa.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.